Investigating the Roles of CD44 and CD147 in Prostate Cancer Metastasis and Drug-Resistance

Total Page:16

File Type:pdf, Size:1020Kb

Investigating the Roles of CD44 and CD147 in Prostate Cancer Metastasis and Drug-Resistance Investigating the roles of CD44 and CD147 in prostate cancer metastasis and drug-resistance Jingli Hao A Thesis submitted for the Degree of Doctor of Philosophy St. George Clinical School Faculty of Medicine University of New South Wales April 2012 ORIGINALITY STATEMENT ‘I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at UNSW or any other educational institution, except where due acknowledgement is made in the thesis. Any contribution made to the research by others, with whom I have worked at UNSW or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project's design and conception or in style, presentation and linguistic expression is acknowledged.’ Signed …………………………………………….............. Date …………………………………………….................. COPYRIGHT STATEMENT ‘I hereby grant the University of New South Wales or its agents the right to archive and to make available my thesis or dissertation in whole or part in the University libraries in all forms of media, now or here after known, subject to the provisions of the Copyright Act 1968. I retain all proprietary rights, such as patent rights. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. I also authorise University Microfilms to use the 350 word abstract of my thesis in Dissertation Abstract International (this is applicable to doctoral theses only). I have either used no substantial portions of copyright material in my thesis or I have obtained permission to use copyright material; where permission has not been granted I have applied/will apply for a partial restriction of the digital copy of my thesis or dissertation.' Signed ……………………………………………........................... Date ……………………………………………........................... AUTHENTICITY STATEMENT ‘I certify that the Library deposit digital copy is a direct equivalent of the final officially approved version of my thesis. No emendation of content has occurred and if there are any minor variations in formatting, they are the result of the conversion to digital format.’ Signed ……………………………………………........................... Date ……………………………………………........................... Abstract Prostate cancer (CaP) is a major health problem in males in western countries. Although early-stage CaP can be controlled using conventional therapies, almost all CaP patients invariably progress to recurrent castration resistant CaP and eventually die from secondary disease. Targeting tumour-associated antigens is fast emerging as an area of promise for late stage CaP. This thesis provides an overview of literature regarding CaP-related issues, with emphasis on the putative roles of the tumour microenvironment and selected tumour-associated antigens, i.e. CD44 and CD147 in CaP. The aims of the study were to: 1) investigate the expression of CD44 and CD147 in primary CaP tissues and various metastatic CaP cell lines, and identify whether CD44 and CD147 are related with CaP progression, whether they are related with multidrug-resistance proteins, and whether these two proteins are inter-related; 2) develop CaP cell lines with down- regulated CD44 and CD147 expression, study the in vitro functions of these molecules in CaP, and the potential mechanisms involved; and 3) develop CaP animal models with CD44/CD147-knock-down (KD) xenografts, and look at the roles of CD44 and CD147 in vivo in respect of tumour growth, metastasis, and drug resistance. The results indicated that CD44 and CD147 are both associated with CaP progression. CD44 and CD147 are co-expressed and interact in CaP cells. KD of CD44 or CD147 enhanced docetaxel sensitivity, reduced CaP invasive potential, and down-regulated main signal modulators associated with cell growth and survival. In vivo, CD44 or CD147-KD PC-3M-luc subcutaneous xenografts showed suppressed tumour growth with increased docetaxel responsiveness compared to control xenografts. Preliminary studies of an intracardiac model showed metastatic spread of PC-3M-luc cells imaged using bioluminescence, indicating this is an appropriate model for future studies assessing the in vivo roles of CD44 and CD147 in tumour spread. These findings suggest that CD44 and CD147 are both closely related with CaP metastasis and drug resistance. Selective targeting of CD44/CD147 alone or combined with docetaxel may limit CaP metastasis and increase chemosensitivity, indicating promise for future CaP treatment. To date, these studies appear to be the first to show that CD44 and CD147 are collaborators in CaP. 4 Acknowledgements I‟m greatly indebted to my supervisor Associate Professor Yong Li, whose support, encouragement and help has been invaluable for the thesis and for my development as a researcher at large. In particular, he supported me during all my research work, encouraged me to apply for several awards and travel grants, encouraged me to go to international and domestic conferences and taught me a lot about how to improve my observations, basic experimental skills, manuscript writing, conference presentation and response to all comments. He reviewed my papers and thesis with a lot of patience and actively sought collaborations which supported my skill development. Without him I could not have written this thesis. My co-supervisor Dr. Michele Madigan has always kindly given me the most sincere advice on not only studying but life in general. She always took time out of her busy schedule to discuss with me about scientific problems and the progress of my project. She always carefully reviewed my papers or thesis, or giving hands on demonstrations to develop my experimental skills. Michele, I‟m lucky to have you as my co-supervisor! I am also grateful to my co-supervisor Dr. Aparajita Khatri. I worked under her supervision during the 2nd year of my PhD in the Oncology Research Center (ORC) in the Prince of Wales Hospital. She imparted a tremendous amount of knowledge about molecular biology on me. Thanks Aparajita for providing a very good research environment for me. I also learned a lot from her Post-doctoral Fellows and Research Assistants. I would like to thank them as well: Dr. Nirupama Verma, Ms. Swapna Joshi, Ms. Xiaochun Wang, and Mr. Zhe Yuan. I made good progress when I was working there. Without them I could not have done so. The animal experiments and the preparation for them greatly benefitted from the help I received from Dr. Carl Power and Dr. Tzong-Tyng Hung. They gave me lots of helpful advice, from ethics applications, experiment designing, experiment techniques, to data analysis. I also learned a lot from them about animal experiments and research ethics. Without them, the animal experiments would not have been completed. I also want to say thank you to Professor Pamela Russell, who kindly introduced me to her research group in the ORC and for sharing her precious research resources with us. To all staff in the Oncology Research Center, the help with all little things is greatly appreciated. 5 I also would like to thank Dr Paul Cozzi at the Urology Sydney and Professor Warick Delprado at the Douglass Hanly Moir Pathology, for kindly providing prostate cancer and benign prostatic hyperplasia (BPH) tissues and clinical data for my study. Otherwise, I could not complete my studies on the primary CaP. In addition, I thank all funding bodies including NHMRC, Cancer Institute NSW, St George and Southerland Medical Research Foundation, Urology Research Fund and Cancer Care Centre Cancer Research Trust Fund for their generous supports. I appreciate all supports from the administrative staff at the St George Clinical School, UNSW and the Cancer Care Centre at St George Hospital (Associate Professor Peter Graham and Professor John Kerasley). Further, I want to thank Ms. Julia Beretov, who helped me with all histology preparation related studies. I want to thank my colleagues and friends in the prostate cancer group in St. George Hospital: Dr. Hongmin Chen, Dr. Hongtu Chao, Dr. Weiwei Xiao, and Dr. Jingjing You, we share happiness and sadness together and help each other to go through difficulties in studying and living. Last but not least, I want to thank my beloved family, my husband Josef who always stands by my side and gives me powerful support. He is not only my partner but also my best friend. I want to thank my parents, Lanyun Hao and Shuangzhen Zhao, for their unlimited love and support through out my life. 6 Publications, Presentations and Awards Publications arising from this thesis Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y. EMMPRIN/CD147 and CD44 are potential therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targ 2010;20:287-306 (IF: 4.8) Hao JL, Chen HM, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado WJ, Russell PJ, Li Y. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters (MCTs) is related with prostate cancer drug resistance and progression. Br J Cancer 2010;103:1008-1018 (IF: 4.8) Hao JL, Madigan MC, Khatri A, Power CA, Hung TT, Beretov J, Xiao W, Cozzi PJ, Graham PH, Kearsley JH, Li Y. CD44 and CD147 modulate prostate cancer cells in vitro and in vivo metastasis and chemoresistance. Submitted to PLoS ONS in a revised version 2012 (IF: 4.4) Book Chapter: Hao JL, Madigan MC Cozzi PJ, Kearsley J, Li Y. Angiogenesis, lymphangiogenesis and vasculogenic mimicry in human prostate cancer therapy. In: Advances in Medicine and Biology. Editor: Leon V. Berhardt. Volume 38. Nova Science Publishers, Inc. USA. Accepted on 31/03/2011 in press. Other publications: Chen H, Wang L, Beretov J, Hao JL, Xiao W, Li Y. Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression.
Recommended publications
  • The Evolving Concept of Cancer and Metastasis Stem Cells
    JCB: Review The evolving concept of cancer and metastasis stem cells Irène Baccelli1,2 and Andreas Trumpp1,2 1Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), D-69120 Heidelberg, Germany 2Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), D-69120 Heidelberg, Germany The cancer stem cell (CSC) concept, which arose more review is to illustrate the current dynamic view of CSCs to fos- than a decade ago, proposed that tumor growth is sus- ter the development of better therapeutic approaches to target this highly complex and deadly disease. tained by a subpopulation of highly malignant cancerous cells. These cells, termed CSCs, comprise the top of the The classical concept of CSCs tumor cell hierarchy and have been isolated from many Adult regenerating tissues (such as the skin, the gastrointes- leukemias and solid tumors. Recent work has discovered tinal mucosa, or the hematopoietic system) are hierarchically Downloaded from that this hierarchy is embedded within a genetically het- organized (Murphy et al., 2005; Fuchs and Nowak, 2008; van erogeneous tumor, in which various related but distinct der Flier and Clevers, 2009; Seita and Weissman, 2010). At the top of the cellular organization, normal adult stem cells subclones compete within the tumor mass. Thus, geneti- maintain tissues during homeostasis and facilitate their regen- cally distinct CSCs exist on top of each subclone, revealing eration, for example in response to infection or to cell loss a highly complex cellular composition of tumors. The CSC due to injury. These physiological stem cells are defined by concept has therefore evolved to better model the complex their functional properties: they have the life-long capacity to jcb.rupress.org and highly dynamic processes of tumorigenesis, tumor self-renew (the ability to give rise to a new stem cell after cell relapse, and metastasis.
    [Show full text]
  • Molecular Interactions of Erbb Receptor Tyrosine Kinases and Integrin Β1: Implications for Tumor Therapy
    THESIS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY (Ph.D.) Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy by Miklós Petrás Supervisor: Prof. János Szöllősi, D.Sc. Álmos Klekner, Ph.D. UNIVERSITY OF DEBRECEN DOCTORAL SCHOOL OF MOLECULAR MEDICINE DEBRECEN, 2013 Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy Miklós Petrás Ph.D. Thesis UNIVERSITY OF DEBRECEN MEDICAL AND HEALTH SCIENCE CENTER DEPARTMENT OF BIOPHYSICS AND CELL BIOLOGY DEPARTMENT OF NEUROSURGERY DEBRECEN, 2013. 2 Ph. D. thesis data Title: Molecular interactions of ErbB receptor tyrosine kinases and integrin β1: implications for tumor therapy Author: Miklós Petrás, M.D. Supervisors: Prof. János Szöllősi, D.Sc. Álmos Klekner, M.D., Ph.D. Doctoral School: "Molecular Medicine" at the University of Debrecen Head of Doctoral School: Prof. László Csernoch, D.Sc. Doctoral examination committee: Chairman: Prof. László Csernoch, D.Sc. Members: Prof. Ferenc Erdődi, D.Sc. Beáta Bugyi, Ph.D. Place and time of doctoral examination: Debrecen, 3 May 2013 Doctoral thesis committee: Chairman: Prof. László Csernoch, D.Sc. Reviewers: Prof. István Jóna, D.Sc. József Tóvári, Ph.D. Members: Prof. Ferenc Erdődi, D.Sc. Beáta Bugyi, Ph.D. Place and time of thesis defence: Debrecen, 3 May 2013 Key words: ErbB (EGFR), integrin, tyrosine kinase, FRET, trastuzumab, PI-3K/Akt, breast cancer, astrocytoma (glioblastoma) 3 "Because strait is the gate, and narrow is the way, which leadeth unto life, and few there be that find it." Matthew 7:14 Bible - King James Version, 1611 Oxford King James Bible (Authorized Version), 1769 4 CONTENTS ABBREVIATIONS ....................................................................................................................................
    [Show full text]
  • University of Groningen PET Imaging and in Silico Analyses to Support
    University of Groningen PET imaging and in silico analyses to support personalized treatment in oncology Moek, Kirsten DOI: 10.33612/diss.112978295 IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2020 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Moek, K. (2020). PET imaging and in silico analyses to support personalized treatment in oncology. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.112978295 Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 30-09-2021 06 The antibody-drug conjugate target landscape across a broad range of tumor types Kirsten L.
    [Show full text]
  • Review Article Cd44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches
    Hindawi Contrast Media & Molecular Imaging Volume 2017, Article ID 2709547, 14 pages https://doi.org/10.1155/2017/2709547 Review Article CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches Diana Spiegelberg1 and Johan Nilvebrant2 1 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden 2Division of Protein Technology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden Correspondence should be addressed to Diana Spiegelberg; [email protected] and Johan Nilvebrant; [email protected] Received 24 February 2017; Revised 23 April 2017; Accepted 21 May 2017; Published 20 June 2017 Academic Editor: Shasha Li Copyright © 2017 Diana Spiegelberg and Johan Nilvebrant. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Head and neck squamous cell carcinoma (HNSCC) is a common and severe cancer with low survival rate in advanced stages. Noninvasive imaging of prognostic and therapeutic biomarkers could provide valuable information for planning and monitoring of the different therapy options. Thus, there is a major interest in development of new tracers towards cancer-specific molecular targets to improve diagnostic imaging and treatment. CD44v6, an oncogenic variant of the cell surface molecule CD44, is a promising molecular target since it exhibits a unique expression pattern in HNSCC and is associated with drug- and radio-resistance. In this review we summarize results from preclinical and clinical investigations of radiolabeled anti-CD44v6 antibody-based tracers: full-length antibodies, Fab, F(ab )2 fragments, and scFvs with particular focus on the engineering of various antibody formats and choice of radiolabel for the use as molecular imaging agents in HNSCC.
    [Show full text]
  • Ep 3178848 A1
    (19) TZZ¥__T (11) EP 3 178 848 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 14.06.2017 Bulletin 2017/24 C07K 16/28 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) (21) Application number: 15198715.3 (22) Date of filing: 09.12.2015 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Cueni, Leah Noëmi et al Designated Extension States: F. Hoffmann-La Roche AG BA ME Patent Department Designated Validation States: Grenzacherstrasse 124 MA MD 4070 Basel (CH) (71) Applicant: F. Hoffmann-La Roche AG 4070 Basel (CH) (54) TYPE II ANTI-CD20 ANTIBODY FOR REDUCING FORMATION OF ANTI-DRUG ANTIBODIES (57) The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent comprising administration of a Type II anti-CD20 antibody, e.g. obinutuzumab, to the subject prior to administration of the therapeutic agent. EP 3 178 848 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 178 848 A1 Description Field of the Invention 5 [0001] The present invention relates to methods of treating a disease, and methods for reduction of the formation of anti-drug antibodies (ADAs) in response to the administration of a therapeutic agent.
    [Show full text]
  • Ep 3321281 A1
    (19) TZZ¥¥ _ __T (11) EP 3 321 281 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.05.2018 Bulletin 2018/20 C07K 14/79 (2006.01) A61K 38/40 (2006.01) A61K 38/00 (2006.01) A61K 38/17 (2006.01) (2006.01) (2006.01) (21) Application number: 17192980.5 A61K 39/395 A61K 39/44 C07K 16/18 (2006.01) (22) Date of filing: 03.08.2012 (84) Designated Contracting States: • TIAN, Mei Mei AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Coquitlam, BC V3J 7E6 (CA) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • VITALIS, Timothy PL PT RO RS SE SI SK SM TR Vancouver, BC V6Z 2N1 (CA) (30) Priority: 05.08.2011 US 201161515792 P (74) Representative: Gowshall, Jonathan Vallance Forresters IP LLP (62) Document number(s) of the earlier application(s) in Skygarden accordance with Art. 76 EPC: Erika-Mann-Strasse 11 12746240.6 / 2 739 649 80636 München (DE) (71) Applicant: biOasis Technologies Inc Remarks: Richmond BC V6X 2W8 (CA) •This application was filed on 25.09.2017 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • JEFFERIES, Wilfred •Claims filed after the date of receipt of the divisional South Surrey, BC V4A 2V5 (CA) application (Rule 68(4) EPC). (54) P97 FRAGMENTS WITH TRANSFER ACTIVITY (57) The present invention is related to fragments of duction of the melanotransferrin fragment conjugated to human melanotransferrin (p97). In particular, this inven- a therapeutic or diagnostic agent to a subject.
    [Show full text]
  • Archivio Istituzionale Open Access Dell'università Di Torino Original
    AperTO - Archivio Istituzionale Open Access dell'Università di Torino Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review This is a pre print version of the following article: Original Citation: Availability: This version is available http://hdl.handle.net/2318/1729977 since 2020-02-22T14:19:20Z Published version: DOI:10.1016/j.critrevonc.2019.05.002 Terms of use: Open Access Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law. (Article begins on next page) 25 September 2021 Leonardo Muratori, Anna La Salvia, Paola Sperone, Massimo Di Maio Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review. Abstract Recurrent or metastatic head and neck squamous-cell carcinomas (R/M HNSCC) are a group of cancers with a very poor prognosis. Many clinical trials testing novel target therapies in this setting are currently ongoing. We performed a systematic review focusing our attention on all clinical trials, ongoing or already published, concerning the use of novel drugs for treatment of R/M HNSCC. We found that the research of novel molecules effective in treatment of R/M HNSCC has been intense during last decade, and nowadays it is still very active.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0166697 A1 Bender (43) Pub
    US 2016O166697A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0166697 A1 Bender (43) Pub. Date: Jun. 16, 2016 (54) METHOD OF TREATING CANCER A619/00 (2006.01) A647/4 (2006.01) (71) Applicant: Intensity Therapeutics, Inc., Westport, A647/8 (2006.01) CT (US) A6II 45/06 (2006.01) A619/08 (2006.01) (72) Inventor: Lewis H. Bender, Redding, CT (US) A 6LX3/555 (2006.01) (52) U.S. Cl. (21) Appl. No.: 15/052,326 CPC. A61K47/12 (2013.01); A61 K9/08 (2013.01); 1-1. A61K 33/24 (2013.01); A61 K3I/555 (22) Filed: Feb. 24, 2016 (2013.01); A61 K47/14 (2013.01); A61K47/18 Related U.S. Application Data (2013.01); A61K 45/06 (2013.01); also (63) Continuation of application No. 14/280,036, filed on May 16, 2014, which is a continuation of application (57) ABSTRACT No. PCT/US2013/059841, filed on Sep. 15, 2013. The invention provides a method for treating cancer using a (60) Provisional application No. 61/779,509, filed on Mar. coadministration strategy that combines local codelivery of a 13, 2013, provisional application No. 61/707,733, therapeutic agent and an intracellular penetration enhancing filed on Sep. 28, 2012, provisional application No. agent, and optionally in further combination with local 61/703,890, filed on Sep. 21, 2012. administration of an immunotherapeutic agent, such as a cancer vaccine or NKTagonist. The invention also provides a Publication Classification method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to Sub (51) Int.
    [Show full text]
  • Immunogen, Inc. Regains Development and Commercialization Rights for Cantuzumab Mertansine
    ImmunoGen, Inc. Regains Development and Commercialization Rights for Cantuzumab Mertansine CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 24, 2003--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the Company has regained the development and commercialization rights for cantuzumab mertansine (huC242-DM1), an anticancer product candidate. In 1999, the Company licensed these rights to SmithKline Beecham, which later became GlaxoSmithKline. Cantuzumab mertansine has been studied in Phase I clinical trials and found to be well tolerated. Initial evidence of biological activity also has been reported. ImmunoGen previously announced that GlaxoSmithKline had notified the Company that advancement of cantuzumab mertansine into Phase II studies was dependent on renegotiation of the product license agreement. Since then, the companies have been in negotiations. Mitchel Sayare, Ph.D., ImmunoGen Chairman and CEO, commented, "We've determined that it is not in the best interests of ImmunoGen to enter into a revised agreement with GlaxoSmithKline. ImmunoGen has regained all rights that were licensed to GlaxoSmithKline. We're excited about the prospects of licensing cantuzumab mertansine to a new marketing partner that would initiate a broad Phase II program for this important product candidate." No payments were made by either company for the return of the product rights to ImmunoGen. ImmunoGen holds the Investigational New Drug application (IND) for cantuzumab mertansine and has rights to all clinical data generated in the Phase I studies. The two companies will work together to ensure a smooth transition of all study data. Cantuzumab mertansine is a Tumor-Activated Prodrug (TAP) compound developed by ImmunoGen. It is composed of the humanized antibody huC242 and the cytotoxic agent DM1.
    [Show full text]
  • Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
    antibodies Review Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates J. Edward Fisher, Jr. Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA; jedward.fi[email protected] Abstract: The targeted delivery of drugs by means of linking them to antibodies (Abs) to form antibody–drug conjugates (ADCs) has become an important approach in oncology and could po- tentially be used in other therapeutic areas. Targeted therapy is aimed at improving clinical efficacy while minimizing adverse reactions. The nonclinical safety assessment of ADCs presents several unique challenges involving the need to examine a complex molecule, each component of which can contribute to the effects observed, in appropriate animal models. Some considerations for the nonclinical safety evaluation of ADCs based on a literature review of ADCs in clinical development (currently or previously) are discussed. Keywords: antibody–drug conjugates; nonclinical safety studies; animal models; drivers of toxicity 1. Introduction In addition to the many therapeutic applications of unconjugated antibodies (Abs), the coupling of Abs to biologically active small molecules via chemical linkers to form antibody–drug conjugates (ADCs) has become an important strategy for increasing drug Citation: Fisher, J.E., Jr. specificity [1,2]. ADCs were initially developed to increase the effectiveness of chemother- Considerations for the Nonclinical apy and reduce its toxicity by delivering cytotoxic molecules directly to tumor cells while Safety Evaluation of Antibody–Drug avoiding damage to healthy cells. The majority of ADCs in clinical development combine Conjugates. Antibodies 2021, 10, 15. monoclonal Abs (mAbs) specific to surface antigens present on particular tumor cells https://doi.org/10.3390/antib10020015 with potent anti-cancer agents for oncology indications.
    [Show full text]
  • WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: Published: A61K 39/00 (2006.01) A61K 47/22 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — with sequence listing part of description (Rule 5.2(a)) PCT/US2017/055620 (22) International Filing Date: 06 October 2017 (06.10.2017) (25) Filing Language: English (26) Publication Langi English (30) Priority Data: 62/404,861 06 October 2016 (06.10.2016) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: TERAN, Alona; 13715 Shenandoah Way, Moorpark, CA 93021 (US). MUNAIM, Qahera; 21025 Lemarsh Street, Unit #G42, Chatsworth, CA 913 11 (US). KHALAF, Nazer; 14 Lauf Street, Worcester, MA 01602 _ (US). KAUSHIK, Rahul, Rajan; 1660 Glider Court, Thou- = sand Oaks, CA 91320 (US). CLOGSTON, Christi, L.; = 601 Country View Place, Camarillo, CA 93010 (US). = CHRISTIAN, Twinkle, R.; 519 W. Gainsborough Road, = Apt. 303, Thousand Oaks, CA 91360 (US). CALLAHAN, — William, J.; 1104 Woodridge Avenue, Thousand Oaks, CA = 91362 (US). — (74) Agent: HONG, Julie, J. et al; Marshall, Gerstein Borun = LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL = 60606-6357 (US). = (81) Designated States (unless otherwise indicated, for every
    [Show full text]
  • Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies
    Chapter 1 Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies Federica Ganci, Andrea Sacconi, Valentina Manciocco, Giuseppe Spriano, Giulia Fontemaggi, Paolo Carlini and Giovanni Blandino Additional information is available at the end of the chapter http://dx.doi.org/10.5772/60081 1. Introduction Head and neck squamous cell carcinoma (HNSCC) comprises 5.5% of all incidence cancers and is the sixth leading cancer worldwide with approximately 600,000 cases reported annually [1, 2]. The vast majority of them are squamous cell carcinomas that originate in the epithelium of the oral cavity, pharynx and larynx. There is a higher incidence rate in males compared to females and the median age of patients with HNSCC is about 60 years [3]. The main risk factors for HNSCC are tobacco smoking and heavy use of alcohol. In particular, alcohol consumption and tobacco smoking have a synergic effect [4]. The contribution of tobacco exposure to HNSCC carcinogenesis is strongly correlated with the time and rate of the person who smokes and has showed to have site-specific differences according to the anatomical regions, with an increase in sensitivity from the oral cavity down to the larynx [5]. In addition, high-risk infection types of human papillomavirus (especially HPV-16 and 18) is emerging as a major cause of a subgroup of HNSCC, particularly those of the oropharynx and oral cavity [2, 6]. The traditional risk factors, tobacco and alcohol use, do not appear to play a contributing role in HPV-positive cancers [7].
    [Show full text]